What is the Aptamer Sciences Inc. stock price forecast?

Aptamer Sciences Inc. is currently trading at ₩851. View real-time AI analysis on Alpha Lenz.

What is Aptamer Sciences Inc. insider trading activity?

View the latest insider trading data for Aptamer Sciences Inc. on Alpha Lenz.

What is Aptamer Sciences Inc.'s P/E ratio?

Aptamer Sciences Inc.'s P/E ratio is -6.0.

Aptamer Sciences Inc.

KRX · 291650

₩851+3(+0.35%)Market closed

Ask about Aptamer Sciences Inc.'s future dividend policy...

Alpha Chat Insight

“Aptamer Sciences Inc. trades at a P/E of -6.0 (undervalued) with modest ROE of -32.1%. 3Y revenue CAGR of 113.9% highlights clear growth momentum.”

Ask for details →

Company Overview

Aptamer Sciences Inc. is a biotechnology company, focusing on the development and application of aptamer technologies to advance various fields of medical science and diagnostics. Aptamers are short, synthetic DNA or RNA molecules that can bind to specific targets, such as proteins or small molecules, with high affinity and specificity. The company leverages these unique properties to create innovative diagnostic solutions and therapeutic agents. Aptamer Sciences Inc. actively collaborates with pharmaceutical and biotechnology firms to enhance the precision and effectiveness of drug discovery and development processes. As part of the growing biotechnology sector, Aptamer Sciences Inc. contributes significantly to advancing personalized medicine and healthcare solutions. Their pioneering work in the aptamer space holds the potential to transform diagnostic methods and therapeutic strategies, underscoring their integral role in the evolving landscape of modern medicine.

CEO한동일

Websitehttps://www.aptsci.com

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2025

Profile

₩51,944,394,942Market Cap

₩3,504,924,220Revenue

61.04MShares Out

0Employees

Margins

48.23%Gross

-178.85%EBITDA

-222.57%Operating

-245.98%Pre-Tax

-245.98%Net

Valuation

-6.02P/E

1.84P/B

14.82EV/Sales

-6.08EV/EBITDA

-5.36P/FCF

Growth (CAGR)

113.88%Rev 3Yr

72.65%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-23.59%ROA

-32.13%ROE

-22.71%ROIC

Financial Health

₩21,376,249,230Cash & Cash Equivalents

₩-8,501,486,250Net Debt

45.61%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Aptamer Sciences Inc. trades at a P/E of -6.0 (undervalued) with modest ROE of -32.1%. 3Y revenue CAGR of 113.9% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Aptamer Sciences Inc. (ticker: 291650) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $51.9B.

The current price is ₩851 with a P/E ratio of -6.02x and P/B of 1.84x.

ROE is -32.13% and operating margin is -222.57%. Annual revenue is $3.5B.